Sanofi announced the launch of the Dupixent® on the Russian market for the treatment of patients with moderate to severe atopic dermatitis aged 18 years and older and as an additional supportive therapy for moderate and severe bronchial asthma in adults and adolescents aged 12 years and older. Russia became the first country where Dupixent® was registered for use in two indications simultaneously.
DUPIXENT is a dual inhibitor of IL-4 and IL-13 signaling and is approved for 3 indications. DUPIXENT can be used with or without topical corticosteroids as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus. as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.
Oksana Monge, General Director of Sanofi in Eurasian region, noted:
“The availability of innovative drug Dupixent® is a huge step forward in helping Russian patients with atopic dermatitis and bronchial asthma. Before the appearance of Dupixent® in Russia, there was no biological therapy for patients with moderate to severe atopic dermatitis, in which patients are often limited even in the simplest daily activities and cannot live life to the fullest. We believe that Dupixent® will fundamentally change the quality of life of patients, and we hope that it will be able to help many patients cope with the difficulties in controlling these serious diseases and return to a full life.”